Piper Jaffray is raising its price target on shares of ViroPharma VPHM to $23 from $20, and it has an Overweight rating on shares.
In a note to investors, Piper Jaffray writes, "We are raising our U.S. sales estimates for Cinryze to $259 million from $253 million this year based on continued momentum in new patient adds. We see further growth opportunities for Cinryze in 2012 and beyond. The European Medicine's Agency (EMEA) recently adopted a positive opinion for Cinryze in hereditary angioedema (HAE) clearing the way for a potential market approval. As a result, we are increasing our price target to $23 from $20."
Shares of VPHM lost $2.14 yesterday to close at $19.67, a loss of 9.8%.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst ColorPrice TargetAnalyst RatingsHealth CareHealth Care SuppliesPharmaceuticalsPiper Jaffray
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in